Article Details
Retrieved on: 2024-11-29 05:56:24
Tags for this article:
Click the tags to see associated articles and topics
Summary
Xbrane Biopharma has raised SEK 125 million through a share issue and SEK 250 million via convertible bonds. This impacts equity securities and may cause stock dilution, supporting production and development projects within the company.
Article found on: www.marketscreener.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here